Vaccinex Inc

VCNX18 Dec 2024
Healthcare
$1.94
-0.61 (-61.37%)
Lowest Today
$1.24
Highest Today
$2
Today’s Open
$1.94
Prev. Close
$3.65
52 Week High
$13.02
52 Week Low
$1.24
To Invest in Vaccinex Inc

Vaccinex Inc

Healthcare
VCNX18 Dec 2024
-0.61 (-61.37%)
1M
3M
6M
1Y
5Y
Low
$1.24
Day’s Range
High
$2
1.24
52 Week Low
$1.24
52-Week Range
52 Week High
$13.02
1.24
1 Day
-
1 Week
-
1 month return
-
3 month return
-46.44%
6 month return
-79.83%
1 Year return
-80.54%
3 Years return
-99.35%
5 Years return
-99.87%
10 Years return
-
Institutional Holdings
Point72 Asset Management, L.P.
6.2
Armistice Capital, LLC
6.13
UBS Group AG
0.13
Fidelity Extended Market Index
0.12
Tower Research Capital LLC
0.07
Fidelity Series Total Market Index
0.04
Vanguard Institutional Extnd Mkt Idx Tr
0.03

Market Status

Fundamentals
Market Cap
9.77 mln
PB Ratio
7.34
PE Ratio
0.49
Enterprise Value
8.55 mln
Total Assets
3.63 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Organisation
Vaccinex Inc
Employees
37
Industry
Biotechnology
CEO
Dr. Maurice  Zauderer Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities